Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Actavis plc (ACT): Allergan, Inc. (AGN)’s Hail Mary Pass Against Bill Ackman

As Allergan, Inc. (NYSE:AGN) receives another blow in its bid to ward off the activist investor, Bill Ackman, CEO of Pershing Square Capital, the only remaining glimmer of hope for the healthcare company might be Actavis plc (NYSE:ACT). CNBC‘s David Faber recalled a rumored Actavis takeover bid for Allergen.

Can hedge funds beat the market

“[…] Proxy from Allergan, Inc. (NYSE:AGN) saying, yeah, we did get approached by another party regarding a potential transaction. We cannot provide assurance on the outcome, or disclose possible terms unless and agreement is reached. That was Actavis plc (NYSE:ACT). That approach was 6 weeks ago or more. The question is, is Activis still there? This is a company that has done numerous deals even over the last year […],” reported Faber.

The recent blow to Allergan, Inc. (NYSE:AGN) is the ruling of a court in California, which allowed Mr. Ackman to exercise voting rights on his 9.7% stake in the company at the December 18th special meeting of Allergan’s shareholders, according to Faber. Furthermore Allergan, Inc. (NYSE:AGN)’s plans to challenge the ruling and hoping for an SEC intervention are also a long shot considering the short time frame until the all important shareholder’s meeting.

However, the curtains have still not closed for Allergan, Inc. (NYSE:AGN), according to the analysts that Faber spoke to. They seem to think that there is still sufficient time to come up with a new plan before the meeting.

Allergan, Inc. (NYSE:AGN) might not be the biggest spender in R&D among the pharmaceutical companies, but it has certainly caught the eye of Bill Ackman, who plans to extract some hidden value from the company, but definitely not in ways that Allergan approves of, and hence the battle between the two ensues.

Allergan, Inc. (NYSE:AGN) is currently down 0.52% for the day and trading at $194.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.